- Home
- LXEO
as 07-26-2024 4:00pm EST
Stocks
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 380.2M | IPO Year: | 2023 |
| Target Price: | $22.29 | AVG Volume (30 days): | 480.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.00 - $22.33 | Next Earning Date: | 08-21-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Lexeo Therapeutics Inc. (LXEO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Jul 10 '24 | Sell | $19.06 | 100 | $1,906.00 | 120,695 | SEC Form 4 |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Jul 10 '24 | Sell | $17.06 | 27,931 | $476,502.86 | 120,795 | SEC Form 4 |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Jul 10 '24 | Sell | $16.85 | 3,347 | $56,396.95 | 148,726 | SEC Form 4 |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Jul 10 '24 | Sell | $16.45 | 23,622 | $388,581.90 | 152,073 | SEC Form 4 |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Jun 10 '24 | Sell | $18.18 | 2,038 | $37,050.84 | 170,695 | SEC Form 4 |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Jun 10 '24 | Sell | $17.29 | 2,962 | $51,212.98 | 172,733 | SEC Form 4 |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | May 13 '24 | Sell | $13.22 | 5,000 | $66,093.00 | 170,695 | SEC Form 4 |
| Omega Fund VI, L.P. | LXEO | 10% Owner | Nov 7 '23 | Buy | $11.00 | 454,545 | $4,999,995.00 | 2,157,623 | SEC Form 4 |
| Lundbeckfond Invest A/S | LXEO | 10% Owner | Nov 7 '23 | Buy | $11.00 | 227,272 | $2,499,992.00 | 1,835,959 | SEC Form 4 |
Latest Lexeo Therapeutics Inc. News
LXEO Breaking Stock News: Dive into LXEO Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Zacks
10 days ago
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
Investor's Business Daily
11 days ago
Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion
MT Newswires
11 days ago
Sector Update: Health Care Stocks Retreat Monday Afternoon
MT Newswires
11 days ago
Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder
MT Newswires
11 days ago
Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers
BioPharma Dive
12 days ago
Lexeo gene therapy shows signs of heart benefit in small study
GlobeNewswire
12 days ago
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Compare LXEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXEO Lexeo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.